Related Experiment Video
Updated: Aug 13, 2025
07:30
Creating Radio-cephalic Arteriovenous Fistula in the Forearm with a Modified No-Touch Technique
Published on: April 1, 2022
7.7K
Sex Differences in Arteriovenous Fistula Failure: Insights from Bioinformatics Analysis
1Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Journal of Cardiovascular Development and Disease
|January 20, 2023
Summary
Sex differences impact arteriovenous fistula (AVF) failure in hemodialysis patients. This study reveals distinct hub genes and immune responses, offering insights for sex-specific treatments to improve AVF patency.
Area of Science:
- Vascular Surgery
- Nephrology
- Bioinformatics
- Immunology
Background:
- Arteriovenous fistulas (AVFs) are crucial for hemodialysis access.
- High AVF failure rates, particularly in female patients, necessitate understanding sex-based disparities.
- Mechanisms underlying sex differences in AVF failure remain largely unknown.
Purpose of the Study:
- To elucidate the molecular mechanisms and sex differences in arteriovenous fistula failure.
- To identify key genes, pathways, and immune responses contributing to AVF failure.
- To explore potential sex-specific therapeutic targets for improving AVF patency.
Main Methods:
- Differential gene expression (DEG) analysis and functional enrichment analysis of the GSE119296 dataset.
- Immune cell infiltration analysis using CIBERSORT.
- Protein-protein interaction network construction and hub gene identification.
- Online drug screening for potential sex-specific therapeutic agents.
Main Results:
- Extracellular matrix reprogramming and PI3K-AKT pathway were significantly enriched in both sexes.
- COL1A1 identified as the hub gene in males; CDK1 identified as the hub gene in females.
- Activated immune responses, including γδ-T cells and mast cells, were observed in female patients.
Conclusions:
- Sex-specific pathogenesis of AVF failure involves distinct hub genes (COL1A1 in males, CDK1 in females) and signaling pathways.
- Sex differences in AVF failure are associated with specific immune abnormalities, particularly in females.
- Identification of potential sex-specific drugs offers new avenues for targeted therapies to prevent AVF failure.
